September 2024 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions

A slow season for biotech IPOs may be coming to an end. In September, four biopharmas have completed NASDAQ listings in which each raised more than $100 million, including Bicara with $315 million IPO. Most recently, Upstream Bio filed for IPO seeking to raise $100 million.

JNJ announced new data from the Phase 1b/2 OrigAMI-1 study, which showed Rybrevant (amivantamab-vmjw) combined with chemotherapy demonstrated promising rapid and durable antitumor activity in patients with RAS/BRAF wild-type metastatic CRC who have not previously received anti-EGFR therapy.